A new study supports the use of a DNA-based “biomarker” blood test as a complement to the prostate-specific antigen test currently offered to screen men for prostate cancer.
A new study supports the use of a DNA-based “biomarker” blood test as a complement to the prostate-specific antigen test currently offered to screen men for prostate cancer.